1. Scrip

Takeda Funds Celiac Asset As Prelude To Potential Acquisition

 
• By Ian Haydock

Takeda has started off the new year by continuing down the path of partnerships to strengthen its core therapeutic areas, this time linking up with a US academic spin-out for a potential oral therapy for celiac disease.

businessman and businesswoman are shaking hands and exchanging folder after agreement was reached

Takeda Pharmaceutical Co. Ltd.'s new alliance with the US startup PvP Biologics appears clearly designed to further strengthen the Japanese company's presence in the gastrointestinal area, one of its core therapeutic fields along with oncology and CNS.

The celiac disease-focused collaboration also represents an early big win for PvP, a university spin-out formed in 2012 that could...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

Competition Weighs On Gilead’s CAR-Ts As Both See Sales Decline

 
• By Alaric DeArment

The quarter saw strong growth overall, but the company now expects sales of Yescarta and Tecartus to fall for the full year 2025 versus 2024 thanks to competition.

More Players, Better Pricing, Tough Equity Market: Royalty Deals Go Mainstream

 
• By Manas Mishra

Royalty deals are on track for another blowout year, but it’s not only because of a depressed biotech market. Large investment firms such as KKR are taking note.

Jazz’s Modeyso Approved For Rare Glioma With Expansion Targeted

 
• By Jessica Merrill

The accelerated approval came three months after Jazz completed the acquisition of Modeyso’s developer, Chimerix.